Propranolol
Propranolol is a non-selective beta blocker used for high blood pressure, heart rhythm disorders, angina, migraine prevention, and performance anxiety. It blocks beta-1 and beta-2 adrenergic receptors, slowing heart rate and reducing blood pressure.
Uses & FDA Indications
Propranolol was the first beta blocker approved for clinical use and remains one of the most widely prescribed drugs in cardiovascular and neurological medicine. Its lipophilicity — the property of dissolving in fat and crossing the blood-brain barrier — gives it a unique profile compared to cardioselective, hydrophilic beta blockers like atenolol and metoprolol.
FDA-approved indications include: hypertension, angina pectoris, atrial fibrillation (rate control), myocardial infarction (secondary prevention), essential tremor, hypertrophic subaortic stenosis, pheochromocytoma (as an adjunct to alpha blockade), migraine prophylaxis, and infantile hemangioma (Hemangeol oral solution for proliferating hemangioma in infants).
Off-label uses include: performance anxiety / situational anxiety, hyperthyroidism and thyroid storm (controlling sympathetic symptoms while definitive treatment is arranged), portal hypertension prophylaxis of variceal bleeding, akathisia (drug-induced restlessness), and PTSD (reducing re-experiencing symptoms, though evidence is mixed).
How It Works
Propranolol is a non-selective beta-adrenergic receptor antagonist, blocking both beta-1 receptors (predominantly in the heart) and beta-2 receptors (in bronchial smooth muscle, peripheral vasculature, and the liver). This non-selectivity is the key pharmacological distinction that defines both its broader therapeutic range and its risks.
Beta-1 blockade in the heart reduces heart rate (negative chronotropy), reduces contractility (negative inotropy), slows AV conduction (negative dromotropy), and lowers blood pressure. These effects underlie its utility in hypertension, angina, arrhythmias, and heart failure (in certain settings). Beta-2 blockade in the lung causes bronchoconstriction — which is largely irrelevant in patients with normal airways but can be life-threatening in patients with asthma or significant COPD.
Propranolol's lipophilicity allows it to cross the blood-brain barrier, explaining its effectiveness for essential tremor (central beta blockade in cerebellar circuits) and anxiety (central adrenergic dampening). This property also contributes to central side effects such as fatigue, depression, vivid dreams, and sleep disturbance that are less common with hydrophilic beta blockers.
Propranolol is a potent inhibitor of CYP2D6, raising plasma levels of drugs metabolized by this enzyme (antidepressants, antipsychotics, certain opioids). It is also extensively metabolized by CYP2D6 itself — poor metabolizers of CYP2D6 may experience higher propranolol exposure and greater bradycardia. Genotyping is not routinely indicated but is worth considering in patients who show unexpected sensitivity.
CONTRAINDICATED IN ASTHMA AND SIGNIFICANT COPD: Beta-2 blockade causes bronchoconstriction. Even a single dose of propranolol can trigger severe bronchospasm in asthmatic patients, potentially fatal. Do not use non-selective beta blockers in asthma. Cardioselective agents (metoprolol, bisoprolol, atenolol) have substantially lower bronchospasm risk if a beta blocker is required in a patient with reactive airway disease — but even they are not without risk and require careful monitoring.
Side Effects
Common
- Bradycardia — reduced heart rate; usually asymptomatic at moderate degrees; symptomatic at very low heart rates
- Hypotension and orthostatic hypotension — dizziness, lightheadedness, fall risk
- Fatigue and exercise intolerance — reduced cardiac output limits peak exercise capacity; very common, often limiting compliance
- Cold extremities — peripheral vasoconstriction (beta-2 blockade); Raynaud-like symptoms possible
- Bronchospasm — serious in susceptible patients; see Warnings
- Depression and mood changes — more common with lipophilic beta blockers (propranolol, metoprolol) than hydrophilic agents
- Sexual dysfunction — erectile dysfunction in men; decreased libido
- Sleep disturbance, vivid dreams, nightmares — from CNS penetration
Masking of Hypoglycemia
Beta blockade blunts the tachycardia that serves as the primary warning sign of hypoglycemia in diabetic patients on insulin or sulfonylureas. Sweating (a cholinergic response) is preserved. Diabetic patients on propranolol should monitor glucose more carefully and be counseled that the usual warning signs may be absent.
Drug Interactions
| Drug / Class | Interaction | Clinical Significance |
|---|---|---|
| Verapamil and Diltiazem (non-dihydropyridine calcium channel blockers) | Both propranolol and these agents independently reduce heart rate and AV conduction. Combination can cause severe bradycardia, heart block, and hemodynamic compromise. IV verapamil in a patient on a beta blocker can be fatal. | High — avoid IV combination; use oral combination with extreme caution and close monitoring |
| Epinephrine (adrenaline) | Propranolol blocks beta-2 vasodilatory receptors; if epinephrine is administered (e.g., for anaphylaxis or in local anesthetics), the alpha-1 vasoconstriction goes unopposed, causing severe hypertensive crisis with reflex bradycardia. | High — alert surgeons and emergency providers; if epinephrine is required for anaphylaxis in a beta-blocked patient, may need higher doses and close monitoring |
| NSAIDs (ibuprofen, naproxen, indomethacin) | NSAIDs reduce prostaglandin-mediated vasodilation and sodium excretion, directly counteracting the antihypertensive effect of beta blockers. Blood pressure control can be meaningfully impaired with regular NSAID use. | Moderate — prefer acetaminophen for analgesia; if NSAIDs required, monitor blood pressure |
| Antidiabetic agents (insulin, sulfonylureas) | Propranolol masks tachycardia from hypoglycemia and prolongs the hypoglycemic episode (beta-2 blockade impairs glycogenolysis). See Side Effects section for clinical implications. | Moderate — important counseling point; monitor glucose more frequently |
| Other antihypertensives | Additive blood pressure reduction; careful dose titration needed when combining antihypertensive agents. | Moderate — clinically useful effect but monitor for excessive hypotension |
| Clonidine | On clonidine withdrawal, propranolol can worsen rebound hypertension by blocking vasodilatory beta-2 receptors. If both are being discontinued, taper clonidine first, then propranolol. | Moderate — sequencing of discontinuation is critical |
Warnings & Contraindications
Contraindications
- Bronchial asthma or severe reactive airway disease
- Cardiogenic shock or decompensated heart failure
- Sinus bradycardia or greater than first-degree heart block (without pacemaker)
- Hypersensitivity to propranolol
Abrupt Discontinuation
In patients with ischemic heart disease, abrupt propranolol withdrawal can precipitate rebound angina, myocardial infarction, and ventricular arrhythmias — sometimes within hours to days of stopping. The mechanism involves upregulation of beta receptors during chronic blockade; on sudden cessation, these sensitized receptors are flooded with catecholamines. Always taper propranolol gradually over one to two weeks, and counsel patients never to run out of medication without a plan for continuation.
Check for interactions between propranolol and your other medications.
Check Drug Interactions →Frequently Asked Questions
Can propranolol help with anxiety?
Propranolol is effective for the physical, somatic symptoms of performance and situational anxiety — the racing heart, trembling hands, sweating, and shaky voice that occur in high-stakes situations like public speaking, musical performances, or presentations. By blocking beta-1 and beta-2 adrenergic receptors peripherally, it prevents the physiological "fight or flight" response from manifesting in the body. Because propranolol is lipophilic and crosses the blood-brain barrier, it may also have some central effect on anxiety circuitry. It is not an approved treatment for generalized anxiety disorder, social anxiety disorder, or panic disorder, though it is used off-label for these purposes. For ongoing anxiety disorders, SSRIs, SNRIs, or therapy are first-line.
Why can't you stop propranolol suddenly?
Abrupt discontinuation of propranolol in patients with coronary artery disease or angina carries a risk of rebound ischemia — potentially triggering unstable angina or myocardial infarction. During chronic beta blockade, the heart upregulates beta-adrenergic receptors. When the blocker is suddenly removed, these extra receptors become exposed to circulating catecholamines all at once, causing a surge in heart rate and myocardial oxygen demand that can exceed coronary supply. In patients without known cardiac disease, abrupt discontinuation is lower risk but should still be avoided. Always taper propranolol gradually over one to two weeks, and do not miss doses, particularly in cardiac patients.
Is propranolol a controlled substance?
No — propranolol is not a controlled substance. It has no abuse potential or euphoric effects and is not scheduled by the DEA. It is available by prescription only, primarily because of its cardiovascular effects and the need for individualized dosing and monitoring. Notably, propranolol has been banned in competitive sports by WADA (World Anti-Doping Agency) in certain precision sports such as archery, shooting, and golf — not because of abuse potential but because its ability to reduce tremor and heart rate confers a performance advantage in steadiness-dependent events.